CJC-1295 (No DAC) + Ipamorelin 10mg Peptide | Third-Party Tested | RemedyX Labs

Order CJC-1295 (No DAC) + Ipamorelin 10mg research peptide online from RemedyX Labs. Verified batch COAs confirm purity and identity. Secure checkout, competitive pricing, and fast shipping.

This lyophilized research blend combines CJC-1295 (No DAC), a growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth-hormone secretagogue that acts on the ghrelin receptor (GHSR-1a). Together they are studied in controlled laboratory models of GH-axis signaling and secretagogue receptor activity. Every batch is independently tested by a third-party laboratory to confirm identity and purity, with batch-specific Certificates of Analysis (COA) available for full transparency. For laboratory research use only. Not for human or animal use. Not intended for diagnostic, therapeutic, clinical, or commercial use.

Cited Research

  • Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I (IGF-I) Secretion by CJC-1295

    This study investigates the efficacy of CJC-1295 in producing sustained elevations of growth hormone and insulin-like growth factor I levels.

    J. Clin. Endocrinol. Metab., 2006

    View source · Read our summary

  • Pulsatile Secretion of Growth Hormone (GH) Persists During CJC-1295 Administration

    Researchers examined whether the pulsatile nature of growth hormone secretion is maintained during the administration of CJC-1295.

    PubMed

    View source · Read our summary

  • Ipamorelin, the first selective growth hormone secretagogue

    This paper identifies ipamorelin as the first selective growth hormone secretagogue.

    PubMed, 1998

    View source · Read our summary

  • Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption

    Researchers assessed the pharmacokinetic profiles of ipamorelin and related peptidyl growth hormone secretagogues, specifically evaluating efficacy through nasal absorption in rats.

    PubMed, 1999

    View source · Read our summary

  • Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog

    This study identifies CJC-1295 as a long-acting growth hormone-releasing factor analog created through bioconjugation with albumin to maintain receptor activation.

    PubMed, 2005

    View source · Read our summary

  • Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults

    This clinical trial assesses the ability of CJC-1295 to produce prolonged stimulation of growth hormone and IGF-I secretion in healthy adult subjects.

    PubMed, 2006

    View source · Read our summary

  • Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

    This study demonstrates that once-daily administration of the GHRH analog CJC-1295 normalizes growth patterns in GHRH knockout mice.

    PubMed, 2006

    View source · Read our summary

  • Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

    This study investigates the efficacy of ipamorelin, functioning as a ghrelin mimetic, in treating postoperative ileus within a rodent model.

    PubMed, 2009

    View source · Read our summary

  • Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

    Researchers performed pharmacokinetic and pharmacodynamic modeling of the growth hormone-releasing peptide ipamorelin in human volunteers.

    PubMed, 1999

    View source · Read our summary

  • Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

    This study evaluated the proof-of-concept for using the ghrelin mimetic ipamorelin to manage postoperative ileus in patients undergoing bowel resection.

    PubMed, 2014

    View source · Read our summary

  • Activation of the GH/IGF-1 axis by CJC-1295: biomarkers of GH and IGF-1 action

    Assesses serum biomarkers after CJC-1295 exposure.

    PubMed, 2009

    View source · Read our summary

  • Netnography of Female Use of the Synthetic Growth Hormone Analogue CJC-1295

    Examines reported use and experiences; it is not a controlled efficacy study.

    PubMed, 2016

    View source · Read our summary

  • A method for confirming CJC-1295 abuse in equine plasma

    Develops LC-MS/MS confirmation of CJC-1295; not an efficacy study.

    PubMed, 2019

    View source · Read our summary

  • Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation

    Reports identification of CJC-1295 in a pharmaceutical preparation.

    PubMed, 2010

    View source · Read our summary

  • An immuno polymerase chain reaction screen for the detection of CJC-1295

    Develops a screening method for CJC-1295.

    PubMed, 2019

    View source · Read our summary

Full research bibliography